Bluesky Facebook Reddit Email

Use of 2 anti-clotting medications following bypass surgery improves outcomes for grafted veins

04.24.18 | JAMA Network

Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Bottom Line: Taking aspirin plus an anti-clotting medication for one year after heart bypass surgery resulted in less narrowing of the vein used to bypass a blocked artery than taking aspirin alone.

Why The Research Is Interesting: Previous data have shown that the rate of failure of a graft of a saphenous vein (a vein from the leg) was approximately 15% to 20% within one year after coronary artery bypass grafting (CABG) surgery and was associated with worse long-term outcomes. Antiplatelet (anti-clotting) therapy with aspirin improves vein graft patency (less narrowing, blockage of the vein). The effect of the anti-clotting drug ticagrelor with or without aspirin on grafted saphenous veins in patients undergoing CABG is unknown.

Who and When : 500 patients who underwent CABG were enrolled in a randomized clinical trial in 2014 and 2015, with final follow-up in early 2017.

What (Study Interventions and Outcomes) : Within 24 hours after CABG, 168 patients received ticagrelor (twice daily) and aspirin (once daily); 166 patients received ticagrelor (twice daily); 166 patients received aspirin (once daily) (interventions); patency of the grafted vein (less than 50% narrowing) one year after CABG (outcome)

How (Study Design) : This was a randomized clinical trial (RCT). RCTs allow for the strongest inferences to be made about the true effect of an intervention. However, not all RCT results can be replicated in real-world settings because patient characteristics or other variables may differ from those studied in the RCT.

Authors: Qiang Zhao, M.D., Ph.D., Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China and coauthors

Study Limitations: The trial was designed specifically to examine saphenous vein graft patency so the results cannot be generalized to include arterial grafts. The trial was not equipped to identify a significant effect on the incidence of major adverse cardiac events or other secondary and bleeding outcomes.

Related material: The editorial, " Ticagrelor Following Coronary Artery Bypass Grafting ," by John H. Alexander, M.D., M.H.S., of Duke University Medical Center, Durham, North Carolina, is also available on the For The Media website .

For more details and to read the full study, please visit the For The Media website .

(doi:10.1001/jama.2018.3197)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Want to embed a link to this report in your story? Link will be live at the embargo time http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2018.3197

JAMA

Keywords

Article Information

Contact Information

Qiang Zhao, M.D., Ph.D.
zq11607@rjh.com.cn

How to Cite This Article

APA:
JAMA Network. (2018, April 24). Use of 2 anti-clotting medications following bypass surgery improves outcomes for grafted veins. Brightsurf News. https://www.brightsurf.com/news/1EK22M71/use-of-2-anti-clotting-medications-following-bypass-surgery-improves-outcomes-for-grafted-veins.html
MLA:
"Use of 2 anti-clotting medications following bypass surgery improves outcomes for grafted veins." Brightsurf News, Apr. 24 2018, https://www.brightsurf.com/news/1EK22M71/use-of-2-anti-clotting-medications-following-bypass-surgery-improves-outcomes-for-grafted-veins.html.